Maria Isabel M. V.
- Country
- Spain
- Department
- ES30017: Hematología y Hemoterapia
Research Overview
- Evaluation of Bomedemstat Versus Best Available Therapy in Essential Thrombocythemia Patients with Hydroxyurea Intolerance or Inadequate Response
- A Phase 3 Randomized Open-Label Study of Imetelstat Versus Best Available Therapy in Intermediate-2 or High-Risk Myelofibrosis Refractory to JAK-Inhibitors
Data & Insights
Has run more than one trial at 22 of 99 partner sites.
Specializations
Hematologic Disorders
This investigator specializes in treating essential thrombocythemia, particularly focusing on cases where patients show inadequate response to conventional treatments. Their research explores therapeutic alternatives for managing platelet disorders.
- Treatment-resistant thrombocythemia
- Platelet count management
- Alternative therapy approaches
Their work addresses therapeutic challenges in patients who cannot tolerate standard treatments.
Myeloproliferative Neoplasms
The investigator has extensive experience in treating myelofibrosis, with particular emphasis on intermediate-2 and high-risk cases. Their expertise includes managing patients who have shown resistance to traditional therapeutic approaches.
- JAK-inhibitor resistant cases
- Advanced myelofibrosis
- Survival outcome optimization
Their research explores novel therapeutic strategies for treating resistant forms of myeloproliferative disorders.
Comparative Therapeutics
The investigator conducts research comparing novel therapeutic agents with established treatments in hematologic conditions. Their work evaluates the efficacy of new treatment approaches against current standard therapies.
- Treatment comparison studies
- Drug response evaluation
- Clinical outcomes assessment
Their research aims to identify more effective treatment options for hematologic disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.